Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) (LEAP)
Sponsor: Mirum Pharmaceuticals, Inc.
Listed as NCT06193928, this observational or N/A phase trial focuses on Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis and remains actively recruiting participants. Sponsored by Mirum Pharmaceuticals, Inc., it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Jun 2025 — Present [monthly]
Recruiting
-
Jan 2025 — Jun 2025 [monthly]
Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
Feb 2024 — Apr 2024 [monthly]
Recruiting
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mirum Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .